Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 7/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 7/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 7/20 | 0.36 |
| ▸ | FPR1 | P21462 | 1/20 | 0.36 |
| ▸ | FPR2 | P25090 | 1/20 | 0.36 |
| ▸ | THRA | P10827 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4291585 | 0.90 | FPR1 (0.38) | MCHR1AOC3FPR1FPR2F10 | |
| SCHEMBL4291593 | 0.90 | FPR1 (0.38) | MCHR1AOC3FPR1FPR2F10 | |
| SCHEMBL4301100 | 0.90 | MCHR1 (0.37) | MCHR1AOC3FPR1FPR2F10 | |
| SCHEMBL4301104 | 0.90 | MCHR1 (0.37) | MCHR1AOC3FPR1FPR2F10 | |
| SCHEMBL4301112 | 0.90 | MCHR1 (0.37) | MCHR1AOC3FPR1FPR2F10 | |
| SCHEMBL4289451 | 0.88 | MCHR1 (0.51) | MCHR1AOC3ITGB3ITGA2BFPR1 | |
| SCHEMBL4289456 | 0.88 | MCHR1 (0.51) | MCHR1AOC3ITGB3ITGA2BFPR1 | |
| SCHEMBL4296340 | 0.87 | FPR1 (0.40) | MCHR1FPR1FPR2F10 | |
| SCHEMBL4296336 | 0.87 | FPR1 (0.40) | MCHR1FPR1FPR2F10 | |
| SCHEMBL4296837 | 0.86 | MCHR1 (0.49) | MCHR1AOC3ITGB3ITGA2BFPR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822495-B2 | Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments | SANOFI (FR) | 2014-09-02 | — | — | US | disclosed |
| EP-1987020-B1 | AZACYCLYL-SUBSTITUTED ARYLDIHYDROISOQUINOLINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SANOFI SA (FR) | 2012-10-03 | — | — | EP | disclosed |
| US-20090264403-A1 | NOVEL AZACYCLYL-SUBSTITUTED ARYLDIHYDROISOQUINOLINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264403-A1 | NOVEL AZACYCLYL-SUBSTITUTED ARYLDIHYDROISOQUINOLINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | MCHR1, MRGPRX1, MRGPRX4 | MCHR1 1/4885AOC3 930/4885ITGB3 3183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.